Summary The pharmacokinetics of 1 3-cis-retinoic acid (1 3cisRA) and its effects on retinol plasma levels were investigated after the first and the last doses in melanoma patients, who participated in a study run to assess tolerance over a long period of a treatment schedule of 1 3cisRA associated with recombinant interferon cu2a . Melanoma patients with regional node metastases after radical surgery were randomized to be treated for 3 months with rlFN-ca2a, 3 x 106 IU s.c. every other day, associated with oral 13cisRA at doses of 20 mg day-' (five patients) or 40 mg every other day (seven patients). Maximum 13cisRA blood concentrations usually occurred 4 h after drug administration, with average values of 406 and 633 ng ml-' (i.e. 1.3 and 2.1 gM) after the 20 and 40 mg dose respectively. The average halflife (t1,2) was approximately 30 h. The maximum concentration, the t,12 and the area under the concentration-time curves from 0 to 48 h (AUCOQ48) of 13cisRA did not change after multiple dosing, whereas the AUCO 48 of its major blood metabolite, 4-oxo-13-cis-retinoic acid, increased. Immediately after 1 3cisRA treatment, retinol plasma levels started to decline and they reached the lowest values (approximately 20% reduction) shortly after the time of maximum 13cisRA concentrations (i.e. 4-12 h after drug intake). Afterwards, values returned to baseline. The amount of retinol reduction in time was correlated with 1 3cisRA maximum concentrations.
patients with radical lymph node dissection (Cascinelli et al, 1994) . Preliminary analysis of the results of the study showed that IFN a2a, at the dose of 3 x 106 IU s.c. 3 times per week for 3 years, increased disease-free survival compared with patients who received surgery alone (Cascinelli et al, 1994) . With the aim of testing the effectiveness of the association of 13cisRA to rIFN-ac2a after radical surgery in melanoma patients with node metastases, a study was carried out to choose the dose of 13cisRA that could be potentially administered together with IFN-a2a for a long period of time. A tolerability trial was therefore designed to assess the toxicity of the association of 13cisRA at the doses of 20 mg day-' or 40 mg every 2 days, to , at the dose of 3 x 106 IU s.c. The results of the trial will be published in a separate paper.
As limited information is available on the pharmacokinetics and metabolism of 13cisRA in cancer patients, the purpose of the study was to evaluate, in patients participating in the trial, the pharmacokinetics of 13cisRA. Moreover, the effects of 13cisRA on endogenous vitamin A (retinol) were evaluated, as few and contrasting results have been reported (Goodman et al, 1982; Berni et al, 1993; Collins et al, 1994; Sass et al, 1995) .
PATIENTS AND METHODS Drugs, patients and protocol
Isotretinoin or 1 3cisRA, administered as 20-mg capsules, and rIFN-a2a, as 3 x 106 IU vials, were supplied by Hoffman La Roche (Basle, Switzerland) . Pharmacokinetics studies were performed in 14 out of 30 patients participating in the tolerability study of rIFN-ax2a associated with 13cisRA, whose protocol was approved by the ethics committee of the Istituto Nazionale Tumori (Milan, Italy) . Subjects were melanoma patients with regional week. This last schedule was tested to evaluate potential toxicity because of the high 13cisRA dosage usually used in the treatment of dermatological disease. Distribution of dosage in different patients followed a randomized criteria (Table 1) . Individual characteristics of the patients are presented in Table 1 . Treatment started 30-35 days after surgery and lasted for 3 months or until onset of major toxicity or recurrent disease.
Sample collection and analytical procedure 13cisRA was ingested as 20-mg capsules after breakfast, which consisted of tea and bread. Blood was obtained immediately before the first drug intake (time 0) and at 1, 2, 3, 4, 6, 8, 12, 20, 24, 36 and 48 h, and for some patients at two other intervals up to 72 h. Immediately after the 48-72 h blood sampling, each subject initiated the 3-month course of dosing, with 13cisRA taken in the morning and rIFN-ac2a in the evening. Blood samples were also collected after the last 13cisRA treatment at the same intervals from drug intake as with the first dose. Blood was collected in heparinized tubes, which were wrapped in aluminium foil; all procedures were performed in the dark. After centrifugation, plasma was kept frozen at -20°C until analysis, but never for more than 1 week. Concentrations of 1 3cisRA, 4-oxo-1 3cisRA and retinol were detected by high-performance liquid chromatography (HPLC). Plasma (200 gl) was added to acetonitrile (400 gl), vortex-mixed, and centrifuged to pellet the precipitated proteins.
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(1 3cisRA) (1 3cisRA) (1 3cisRA) (ng ml-') (.gg h ml-') (h) (tgg h ml-') (ng ml-') (igg h ml-') (h) (gg h ml-') (I) (I) (n) and regression coefficients (b) of retinol vs time after the first dose of 13cisRA in melanoma patients. 13cisRA Cma. is reported as ng ml-', and b, which was negative, is reported as absolute values 26 ng ml-1 in 7 out of 14 patients and they were lower than 10 ng ml', which corresponds to the limit of 13cisRA sensitivity, in the remaining patients (data not shown). The concentrations of 13cisRA rose rapidly, and maximum blood concentrations (Cmax) occurred after 4, 3 and 11 h in eight, five and one patient, respectively, with a mean time to peak of 4 h (data not shown). 13cisRA was rapidly metabolized to 4-oxo-13cisRA, and the levels of this metabolite soon became higher than those of the parent drug. No patient had detectable levels of all-transRA (limit of sensitivity, 5 ng ml-'). In 4 out of 14 patients, a secondary maximum concentration of 13cisRA was observed, and this occurred shortly after the first peak, as shown in Figure 2 . The single and average pharmacokinetics parameters after the first and repeated doses are reported in Table 2 . High inter-patient variability was observed. After the first dose, maximum blood concentrations of 13cisRA ranged from 168 to 680 ng ml-l with an average value of 406 ng ml' (i.e. received the 40-mg dose, and those of the t,,2 were similar to those found after the other two doses. Three patients (9, 14 and 26) stopped treatment after 2 months because of recurrent disease, therefore blood was sampled after the last dose. Blood sampling was not performed in patient number nine. There was no difference in the average maximum concentrations, the half-lives and the AUC 048 values after the first and repeated doses. The average ratio of AUC,0-8 after repeated doses to AUC 0-8 after the first dose was approximately 1. Conversely, the AUC 0-48 of the metabolite 4-oxo-13cisRA increased after repeated doses, and the ratios of metabolite AUC048 to parent drug AUC,, 08 increased from 1.7
after the first dose to 2.8 and 3.1 after repeated doses.
Effect of 13cis RA on retinol plasma concentrations
With respect to the influence of 13cisRA on endogenous retinol, immediately after 13cisRA dosing, retinol plasma concentrations started to decrease slightly but progressively, and the lowest concentrations were reached at the time of 1 3cisRA Cmax or slightly later (see Figure 1) . Afterwards, retinol concentrations increased and baseline values were recovered. On average, baseline retinol levels were reduced by 20% and this occurred in the range of 4-12 h (Table 3) . A similar effect on retinol levels was observed after multiple dosing (data not shown). Regression analysis of retinol concentrations vs time (from time 0 to the last time before retinol concentration started to increase) was performed (Table 3 ). All the regression coefficients (b) were statistically significant except for patient number 26, who had the lowest 1 3cisRA peak levels. Regression analysis was not performed for patient number 27 because, as a result of blood haemolysis, the retinol peak was masked in most blood samples. The plot of the Cma vs the retinol regression coefficients (reported as absolute values in Figure 3 ) evidenced a very good correlation between these two variables (r = 0.85), indicating that the higher the 13cisRA Cmax the higher the reduction of retinol.
DISCUSSION
This report describes the pharmacokinetics of 13cisRA in melanoma patients with regional node metastases who had been submitted to radical surgery, and it also describes the influence of this retinoid on endogenous retinol plasma levels. Oral 13cisRA administration at doses of 20 and 40 mg in stage III melanoma patients resulted in average drug maximum concentrations of 1.3 and 2 gM respectively. Nothing can be said about peaks achievable with the 1 mg kg-1 dose, as only two patients were studied after this dose. It is known that gastrointestinal absorption of 13cisRA (Colbum et al, 1983) , as well as that of other retinoids, is influenced by food intake and composition. All the patients analysed in the study received the 13cisRA dose after a similar light breakfast. In spite of this, there was up to an eight-fold variation in peak plasma levels in patients receiving the same dose. This variability was still evident when peak levels were considered, taking into account the dose administered on a mg m-2 basis. Peak levels similar to those achieved in melanoma patients after the 20-and 40-mg doses have been reported after treatment with higher doses of 13cisRA. Maximum blood concentrations ranged from 98 to 535 ng ml-', with an average value of 262 ng ml1 (i.e. 0.9 tM) in patients with cystic acne treated with 80 mg of 13cisRA (Brazzell et al, 1983) , and they ranged from 74 to 511 ng ml-l (i.e. from 0.3 to 1.7 gM) in healthy volunteers receiving a 100 mg per dose (Khoo et al, 1982) . In addition, in these two studies food intake could not account for variability in absorption as the drug was administered after an overnight fast. Doses even higher, i.e. 3, 4 and 5 mg kg-', have been administered to advanced cancer patients, and maximum 13cisRA blood concentrations of 2.5 gM were achieved after the 5 mg kg-' dose (Goodman et al, 1982) . In children with neuroblastoma treated with the maximum tolerated dose of 160 mg m-2 day-', the average 13cisRA peak levels was 7.4 gM (Villablanca et al, 1995) . From all these data it is clear that after administration of the same dose of 13cisRA, there is a marked variability in maximum drug blood concentrations (Brazzell et al, 1983; Goodman et al, 1982 (Goodman et al, 1982) .
In patients suffering from cystic acne and in patients with various keratinization disorders, the half-lives were 10 and 16 h respectively (Brazzell et al, 1983) , and in male volunteers the half-life was 20 h (Khoo et al, 1982) . The differences between 13cisRA half-life in cancer and non-cancer patients might be due to differences in age.
In melanoma patients, the maximum 13cisRA concentrations, the AUCs and the elimination half-lives of 13cisRA after repeated treatments were similar on average to those of the first dose. Conversely, the AUC of the metabolite 4-oxo-13cisRA after repeated doses was greater than after the first dose. Thus, as reported in previous studies (Brazzell et al, 1983) , the pharmacokinetics of 13cisRA does not change during continuous treatment.
Between the first and the last 13cisRA dose melanoma patients received IFN-a2a associated with 13cisRA. Although no conclusion can be drawn, no interaction seems to occur on the pharmacokinetics of 13cisRA by its association with IFN-a2a, as the observed 13cisRA pharmacokinetics was similar to that of repeated doses of 13cisRA as a single agent (Brazzell et al, 1983 ). None of the melanoma patients had detectable levels (i.e. .5 ng ml-) of all-transRA before or after treatment. Such findings are in contrast with previous results in advanced cancer patients treated with high doses of 13cisRA (3, 4 and 5 mg kg-') (Goodman et al, 1982) . In these patients, all-transRA was detected in the plasma of most patients, and its concentrations varied from 0% to 30% of the 13cisRA concentrations.
Analysis of the influence of 13cisRA on plasma retinol demonstrated that the retinoid causes a temporary reduction in retinol concentration. After the doses of 20 and 40 mg, the reduction was very slight. Baseline values were reduced on average by only 20%. However, such a reduction was associated with a statistically significant regression of retinol levels in all the patients except the one who had the lowest 13cisRA peak levels. The influence of 13cisRA on retinol plasma levels is confirmed by the correlation found between 13cisRA C and the amount of retinol reduction.
max
The results are in agreement with previous observations of decreased plasma retinol concentration in the rat after treatment with 13cisRA (Berni et al, 1993; Collins et al, 1994) and with other retinoids with modifications in the area of the retinol hydroxyl end group, such as all-transRA and fenretinide (4HPR) (Bemi et al, 1993) . In rats, although after administration of equimolar doses 13cisRA was slightly less potent than the other retinoids, it caused a remarkable and dose-dependent reduction in plasma retinol concentrations (Bemi et al, 1993) . Fenretinide (4HPR), which is less toxic than 13cisRA and is administered at higher doses, causes a reduction in retinol plasma levels in humans that is proportional to the dose (Formelli et al, 1989) . In breast cancer patients, retinol levels were reduced by approximately 40% 24 h after 4HPR at the dose of 200 mg, i.e. a dose five-to ten-fold higher than that of 13cisRA herein investigated. Other authors have reported no changes in the plasma retinol concentration following 13cisRA treatment in humans (Goodman et al, 1982; Sass et al, 1995) . As in such studies patients received 13cisRA doses similar (Sass et al, 1995) or higher (Goodman et al, 1982) than those herein investigated, a possible explanation for the discordance of the results is the time of blood sampling for retinol analysis. As we have shown, 1660 F Formelli et al after 13cisRA treatment, retinol levels progressively decreased, with the maximum effect occurring shortly after the maximum 1 3cisRA concentrations. In the previously reported papers (Goodman et al, 1982; Sass et al, 1995) , no indication is given on the interval between drug intake and retinol assay.
